Nulibry(fosdenopterin)
Nulibry (fosdenopterin) is a small molecule pharmaceutical. Fosdenopterin was first approved as Nulibry on 2021-02-26. It has been approved in Europe to treat inborn errors metal metabolism.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Nulibry
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fosdenopterin hydrobromide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NULIBRY | Sentynl Therapeutics | N-214018 RX | 2021-02-26 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| nulibry | New Drug Application | 2022-10-28 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
FOSDENOPTERIN HYDROBROMIDE, NULIBRY, SENTYNL THERAPS INC | |||
| 2028-02-26 | ODE-342 | ||
| 2026-02-26 | NCE | ||
| 2025-10-27 | M-286 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Fosdenopterin Hydrobromide, Nulibry, Sentynl Theraps Inc | |||
| 7504095 | 2025-01-31 | DP | U-3092 |
HCPCS
No data
Clinical
Clinical Trials
8 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inborn errors metal metabolism | D008664 | — | — | 1 | 3 | 1 | — | 1 | 4 |
| Pseudomyxoma peritonei | D011553 | EFO_0007456 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemophilia b | D002836 | — | D67 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | — | — | — | — | — | — | 1 | 1 |
| Developmental disabilities | D002658 | EFO_0003852 | F89 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Fosdenopterin |
| INN | fosdenopterin |
| Description | Fosdenopterin (or cyclic pyranopterin monophosphate, cPMP), sold under the brand name Nulibry, is a medication used to reduce the risk of death due to a rare genetic disease known as molybdenum cofactor deficiency type A (MoCD-A).
|
| Classification | Small molecule |
| Drug class | phosphoro-derivatives; pteridine derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1nc(=O)c2c([nH]1)N[C@@H]1O[C@@H]3COP(=O)(O)O[C@@H]3C(O)(O)[C@@H]1N2 |
Identifiers
| PDB | — |
| CAS-ID | 150829-29-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2338675 |
| ChEBI ID | 60210 |
| PubChem CID | 135894389 |
| DrugBank | DB16628 |
| UNII ID | 4X7K2681Y7 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 477 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use